1. Home
  2. WOR vs TGTX Comparison

WOR vs TGTX Comparison

Compare WOR & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Worthington Enterprises Inc.

WOR

Worthington Enterprises Inc.

HOLD

Current Price

$58.06

Market Cap

2.8B

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$31.54

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WOR
TGTX
Founded
1955
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Aerospace
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
5.5B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
WOR
TGTX
Price
$58.06
$31.54
Analyst Decision
Buy
Strong Buy
Analyst Count
3
4
Target Price
$61.00
$54.75
AVG Volume (30 Days)
141.9K
1.6M
Earning Date
12-16-2025
11-03-2025
Dividend Yield
1.30%
N/A
EPS Growth
179.34
N/A
EPS
2.14
2.78
Revenue
$1,200,161,000.00
$531,898,000.00
Revenue This Year
$14.93
$87.88
Revenue Next Year
$4.45
$48.75
P/E Ratio
$27.27
$11.29
Revenue Growth
0.76
100.88
52 Week Low
$37.88
$25.28
52 Week High
$70.91
$46.48

Technical Indicators

Market Signals
Indicator
WOR
TGTX
Relative Strength Index (RSI) 65.98 47.58
Support Level $54.59 $29.50
Resistance Level $55.79 $32.26
Average True Range (ATR) 1.04 1.06
MACD 0.49 0.05
Stochastic Oscillator 98.12 44.11

Price Performance

Historical Comparison
WOR
TGTX

About WOR Worthington Enterprises Inc.

Worthington Enterprises Inc is a designer and manufacturer of products and services, including manufactured metal products. The company operates under two reportable operating segments: Consumer Products and Building Products. The consumer Products business has a diverse product offering in the tools, outdoor living and celebrations categories, including propane-filled cylinders for torches, handheld torches, specialized hand tools, drywall tools, accessories and gas grills, and others. And the Building Products business engaged in providing pressurized containment solutions, providing critical components in the residential, non-residential, and repair and remodel end markets through essential categories. The company derives majority of the revenue from Building Products segment.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Share on Social Networks: